Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery are sponsoring OBN’s PharmaTuesday industry debate on Pharma Externalisation on April 14th 2015

OBN PharmaTuesday – Should Pharma Externalization go to 100%?

Chesterford Research Park, Little Chesterford, CB10 1XL
Tuesday, 14 April 2015 from 18:00 to 21:30

Senior speakers from all sides of the industry will debate the contentious question whether biotech really can afford for big pharma to externalise R&D completely.

Paul Clewlow, Senior Vice President – Business Development at Sygnature Discovery who are sponsoring the debate will make an address and then hand over to the panel:
Simon Hirst, CEO, Sygnature Discovery
Rob Pinnock, Director, Business Development & Licensing MRL, MSD
Georg Buchner, Licensing Director, Europe, Amgen
Richard Mason, CEO, X01
Ann Connolly, Senior Director New Ventures, Johnson & Johnson Innovation

Ian Moules, Senior Director, Search & Evaluation, Global Licensing & Business Development, Takeda Pharmaceuticals

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.